Literature DB >> 3012017

Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine.

A L Gundlach, B L Largent, S H Snyder.   

Abstract

(+)3H-3-PPP [(+)3H-3-(3-Hydroxyphenyl)-N-(1-propyl)-piperidine] binds with high affinity to brain membranes with a pharmacological profile consistent with that of sigma receptors. The distribution of (+)3H-3-PPP binding sites in brain and spinal cord of both guinea pig and rat has been determined by in vitro autoradiography with binding densities quantitated by computer-assisted densitometry. (+)3H-3-PPP binding to slide-mounted brain sections is saturable and displays high affinity and a pharmacological specificity very similar to sites labeled in homogenates. (+)3H-3-PPP binding sites are heterogeneously distributed. Highest concentrations of binding sites occur in spinal cord, particularly the ventral horn and dorsal root ganglia; the pons-medulla, associated with the cranial nerve and pontine nuclei and throughout the brain stem reticular formation; the cerebellum, over the Purkinje cell layer; the midbrain, particularly the central gray and red nucleus; and hippocampus, over the pyramidal cell layer. Lowest levels are seen in the basal ganglia and parts of the thalamus, while all other areas, including hypothalamus and cerebral cortex, exhibit moderate grain densities. Quinolinic acid-induced lesions of the hippocampus indicate that (+)3H-3-PPP labels hippocampal pyramidal cells and granule cells in the dentate gyrus. Intrastriatal injection of ibotenic acid dramatically reduces (+)3H-3-PPP binding in this area, while injection of 6-hydroxydopamine produces a relatively slight decrease. The distribution of (+)3H-3-PPP binding sites does not correlate with the receptor distribution of any recognized neurotransmitter or neuropeptide, including dopamine. However, there is a notable similarity between the distribution of (+)3H-3-PPP sites and high-affinity binding sites for psychotomimetic opioids, such as the benzomorphan (+)SKF 10,047.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3012017      PMCID: PMC6568729     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  63 in total

1.  Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N,N'-dimethyltryptamine forming enzyme, indole-N-methyl transferase.

Authors:  T A Mavlyutov; M L Epstein; P Liu; Y I Verbny; L Ziskind-Conhaim; A E Ruoho
Journal:  Neuroscience       Date:  2012-01-04       Impact factor: 3.590

2.  Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain.

Authors:  T Kobayashi; K Matsuno; M Murai; S Mita
Journal:  Neurochem Res       Date:  1997-09       Impact factor: 3.996

3.  Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine.

Authors:  Rae R Matsumoto; Su-Min Li; Jonathan L Katz; William E Fantegrossi; Andrew Coop
Journal:  Drug Alcohol Depend       Date:  2011-03-21       Impact factor: 4.492

4.  Electrophysiological evidence for the implication of cholecystokinin in the modulation of the N-methyl-D-aspartate response by sigma ligands in the rat CA3 dorsal hippocampus.

Authors:  B Gronier; G Debonnel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

5.  The effect of the pyridyl nitrogen position in pyridylpiperazine sigma ligands.

Authors:  Lidiya Stavitskaya; Michael J Seminerio; Marilyn M Matthews-Tsourounis; Rae R Matsumoto; Andrew Coop
Journal:  Bioorg Med Chem Lett       Date:  2010-03-01       Impact factor: 2.823

6.  Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice.

Authors:  Jiajia Wang; Aisha L Mack; Andrew Coop; Rae R Matsumoto
Journal:  Eur Neuropsychopharmacol       Date:  2007-03-21       Impact factor: 4.600

7.  The sigma receptor: evolution of the concept in neuropsychopharmacology.

Authors:  T Hayashi; Tp Su
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 8.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Lack of sigma-1 receptor exacerbates ALS progression in mice.

Authors:  T A Mavlyutov; M L Epstein; Y I Verbny; M S Huerta; I Zaitoun; L Ziskind-Conhaim; A E Ruoho
Journal:  Neuroscience       Date:  2013-02-28       Impact factor: 3.590

10.  Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding.

Authors:  Felix J Kim; Ivanka Kovalyshyn; Maxim Burgman; Claire Neilan; Chih-Cheng Chien; Gavril W Pasternak
Journal:  Mol Pharmacol       Date:  2010-01-20       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.